Pavinetant Explained

Pavinetant (; developmental code names MLE-4901, AZD-4901, AZ-12472520, AZD-2624), is a small-molecule, orally active, selective neurokinin-3 (NK3) receptor antagonist which was under development by AstraZeneca and Millendo Therapeutics for the treatment of hot flashes and polycystic ovary syndrome (PCOS).[1] [2] [3] It was also under investigation for the treatment of schizophrenia, but development was discontinued for this indication due to lack of effectiveness.[4] In November 2017, development of the medication for hot flashes and PCOS was also terminated after its developer assessed the clinical risks and benefits.

See also

External links

Notes and References

  1. Web site: Pavinetant - Millendo Therapeutics - AdisInsight.
  2. Malherbe P, Ballard TM, Ratni H . Tachykinin neurokinin 3 receptor antagonists: a patent review (2005 - 2010) . Expert Opin Ther Pat . 21 . 5 . 637–55 . 2011 . 21417773 . 10.1517/13543776.2011.568482 . 207473995 .
  3. Sassarini J, Anderson RA . New pathways in the treatment for menopausal hot flushes . Lancet . 389. 10081. 1775–1777. 2017 . 28385351 . 10.1016/S0140-6736(17)30886-3 . free . 20.500.11820/f7c16947-678f-40f6-ac53-73343a9d44e7 . free .
  4. Litman RE, Smith MA, Desai DG, Simpson T, Sweitzer D, Kanes SJ . The selective neurokinin 3 antagonist AZD2624 does not improve symptoms or cognition in schizophrenia: a proof-of-principle study . J Clin Psychopharmacol . 34 . 2 . 199–204 . 2014 . 24525659 . 10.1097/JCP.0000000000000071 . 33936765 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Pavinetant".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.